The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease

被引:26
|
作者
Moss, M. Elizabeth [1 ,2 ]
Carvajal, Brigett [1 ,2 ]
Jaffe, Iris Z. [1 ,2 ]
机构
[1] Tufts Med Ctr, Mol Cardiol Res Inst, 800 Washington Ave,Box 80, Boston, MA 02111 USA
[2] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA
基金
美国国家卫生研究院;
关键词
Endothelial cell; Mineralocorticoid receptor; Cardiovascular disease; Sex differences; Aldosterone; Estrogen; SELECTIVE ALDOSTERONE BLOCKER; EPITHELIAL SODIUM-CHANNEL; RESISTANT HYPERTENSION FOCUS; PRESERVED EJECTION FRACTION; POLYCYSTIC-OVARY-SYNDROME; INDUCED OXIDATIVE STRESS; INTIMA-MEDIA THICKNESS; HEART-FAILURE; DIASTOLIC DYSFUNCTION; BLOOD-PRESSURE;
D O I
10.1016/j.pharmthera.2019.06.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiovascular disease remains the leading cause of death for both men and women. The observation that premenopausal women are protected from cardiovascular disease relative to age-matched men, and that this protection is lost with menopause, has led to extensive study of the role of sex steroid hormones in the pathogenesis of cardiovascular disease. However, the molecular basis for sex differences in cardiovascular disease is still not fully understood, limiting the ability to tailor therapies to male and female patients. Therefore, there is a growing need to investigate molecular pathways outside of traditional sex hormone signaling to fully understand sex differences in cardiovascular disease. Emerging evidence points to the mineralocorticoid receptor (MR), a steroid hormone receptor activated by the adrenal hormone aldosterone, as one such mediator of cardiovascular disease risk, potentially serving as a sex-dependent link between cardiovascular risk factors and disease. Enhanced activation of the MR by aldosterone is associated with increased risk of cardiovascular disease. Emerging evidence implicates the MR specifically within the endothelial cells lining the blood vessels in mediating some of the sex differences observed in cardiovascular pathology. This review summarizes the available clinical and preclinical literature concerning the role of the MR in the pathophysiology of endothelial dysfunction, hypertension, atherosclerosis, and heart failure, with a special emphasis on sex differences in the role of endothelial-specific MR in these pathologies. The available data regarding the molecular mechanisms by which endothelial-specific MR may contribute to sex differences in cardiovascular disease is also summarized. A paradigm emerges from synthesis of the literature in which endothelial-specific MR regulates vascular function in a sex-dependent manner in response to cardiovascular risk factors to contribute to disease. Limitations in this field include the relative paucity of women in clinical trials and, until recently, the nearly exclusive use of male animals in preclinical investigations. Enhanced understanding of the sex-specific roles of endothelial MR could lead to novel mechanistic insights underlying sex differences in cardiovascular disease incidence and outcomes and could identify additional therapeutic targets to effectively treat cardiovascular disease in men and women. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Sex Differences in Circulating Biomarkers of Cardiovascular Disease
    Lau, Emily S.
    Paniagua, Samantha M.
    Guseh, James Sawalla
    Bhambhani, Vijeta
    Zanni, Markella V.
    Courchesne, Paul
    Lyass, Asya
    Larson, Martin G.
    Levy, Daniel
    Ho, Jennifer E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (12) : 1543 - 1553
  • [22] Sex Differences in the Developmental Origins of Cardiovascular Disease
    Intapad, Suttira
    Ojeda, Norma B.
    Dasinger, John Henry
    Alexander, Barbara T.
    PHYSIOLOGY, 2014, 29 (02) : 122 - 132
  • [23] MECHANISTIC PATHWAYS OF SEX DIFFERENCES IN CARDIOVASCULAR DISEASE
    Regitz-Zagrosek, Vera
    Kararigas, Georgios
    PHYSIOLOGICAL REVIEWS, 2017, 97 (01) : 1 - 37
  • [24] The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease
    Davel, Ana P.
    Anwar, Imran J.
    Jaffe, Iris Z.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2017, 26 (02): : 97 - 104
  • [25] Cell-specific regulation of mineralocorticoid receptor signalling in cardiovascular disease
    Young, Morag J.
    ENDOCRINE JOURNAL, 2010, 57 : S304 - S304
  • [26] Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism
    Epstein, Murray
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (12): : 993 - 1003
  • [27] Mineralocorticoid receptor antagonists and endothelial function
    Maron, Bradley A.
    Leopold, Jane A.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (09) : 963 - 969
  • [28] Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms
    Bauersachs, Johann
    Lother, Achim
    KIDNEY INTERNATIONAL SUPPLEMENTS, 2022, 12 (01) : 19 - 26
  • [29] Mineralocorticoid Receptor and Endothelial Dysfunction in Hypertension
    Faulkner, Jessica L.
    de Chantemele, Eric J. Belin
    CURRENT HYPERTENSION REPORTS, 2019, 21 (10)
  • [30] Mineralocorticoid Receptor and Endothelial Dysfunction in Hypertension
    Jessica L. Faulkner
    Eric J. Belin de Chantemèle
    Current Hypertension Reports, 2019, 21